RT Journal Article
SR Electronic
T1 Predictors of BTS Step 3 paediatric asthma prescribing
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1171
VO 44
IS Suppl 58
A1 Clare S. Murray
A1 Stephen Turner
A1 Mike Thomas
A1 Kathryn Richardson
A1 Annie Burden
A1 Daniel West
A1 David Price
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1171.abstract
AB Aim: To identify patient characteristics associated with British Thoracic Society (BTS) Step 3 prescribing options in paediatric asthma.Method: Clinical records of asthma patients aged 5–12yrs receiving inhaled corticosteroids(ICS)±reliever in the year prior to BTS Step 3 therapy initiation were selected from two UK research databases. Multivariate associations between characteristics in the pre step-up year were evaluated relative to addition of long-acting beta-agonist therapy (+LABA) using multinomial logistic regression.Results: Of 10974 cases, 58% had ICS increased (INC), 21% LABA added (+LABA); 10% switched to combination ICS/LABA (FDC) and 10% had leukotriene receptor antagonist added (+LTRA).View this table:Multivariate odds ratios relative to the +LABA cohort.Conclusion: Clinicians often deviate from guidance to add LABA at BTS Step 3. Here we identify factors that influence prescribing choice. On-going work will determine which options lead to better outcomes.